The study by Quigley and Broman aims to estimate the number of people with open-angle glaucoma (OAG) and angle closure glaucoma (ACG) in 2010 and 2020. Using prevalence models based on published data from population-based studies, they constructed models for OAG and ACG by age, sex, and ethnicity, weighted by study sample size. Combining these models with UN population projections, they estimated that there would be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020. OAG will account for 74% of these cases, with women comprising 55% of OAG and 70% of ACG. Asians will represent 47% of those with glaucoma and 87% of those with ACG. Bilateral blindness from OAG and ACG is expected to affect 4.5 million and 3.9 million people, respectively, in 2010, rising to 5.9 and 5.3 million in 2020. The study concludes that glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians. Public health planning requires accurate estimation of disease burden for major disorders.The study by Quigley and Broman aims to estimate the number of people with open-angle glaucoma (OAG) and angle closure glaucoma (ACG) in 2010 and 2020. Using prevalence models based on published data from population-based studies, they constructed models for OAG and ACG by age, sex, and ethnicity, weighted by study sample size. Combining these models with UN population projections, they estimated that there would be 60.5 million people with OAG and ACG in 2010, increasing to 79.6 million by 2020. OAG will account for 74% of these cases, with women comprising 55% of OAG and 70% of ACG. Asians will represent 47% of those with glaucoma and 87% of those with ACG. Bilateral blindness from OAG and ACG is expected to affect 4.5 million and 3.9 million people, respectively, in 2010, rising to 5.9 and 5.3 million in 2020. The study concludes that glaucoma is the second leading cause of blindness worldwide, disproportionately affecting women and Asians. Public health planning requires accurate estimation of disease burden for major disorders.